Slide 1: H1/2025 & Q2/2025 Investors Call
August 2025 H1/2025 & Q2/2025 Investors Call NASDAQ: KMDA; TASE: KMDA.TA
Slide 2: Forward-Looking Statement
FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials
Slide 3: H1-25 Continuing the Growth
H1 - 25 CONTINUING THE GROWTH YoY DOUBLE DIGIT REVENUE AND PROFITABLE INCREASE Paid special cash dividend of $0.20 per share (totaling approximately $11.5M) on April 7, 2025 GROSS PROFIT REVENUE 11% 2024 $35.7 2025 $39.7 11% 2024 $80.2 2025 $88.8 Adj. EBITDA EPS 35% 2024 $16.6 2025 $22.5 58% 2024 $0
Slide 4: Annual Double-Digit Growth Trajectory
4 6 18 24 34 40 - 44 1 2021 2022 2023 2024 2025 2025 represents annual guidance 104 129 142 161 178 - 182 2021 2022 2023 2024 2025 2025 represents annual guidance ADJUSTED EBITDA US$M 61% CAGR ANNUAL DOUBLE - DIGIT GROWTH TRAJECTORY REVENUES US$M 15% CAGR Quarter - End Strong Cash Position of $66.0
Slide 5: Delivering on Our Commitments
DELIVERING ON OUR COMMITMENTS 5
Slide 6: Kamada's Roadmap for Continued Annual Double-Digit Growth
KAMADA’S ROADMAP FOR CONTINUED ANNUAL DOUBLE - DIGIT GROWTH M&A Transactions Support growth through M&A transactions Organic Growth Portfolio of 6 FDA - approved products; Over 30 territories; and Distribution portfolio in Israel Plasma Collection Centers Each new center expected to contribute annua
Slide 7: CYTOGAM CMV Immune Globulin
CYTOGAM CMV IMMUNE GLOBULIN CYTOGAM is the only plasma - derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the leading cause for organ rejection post - transplant Launched, in collaboration with multiple KOLs, a post - marketing rese
Slide 8: Distribution Segment Growth
DISTRIBUTION SEGMENT GROWTH EXCLUSIVE DISTRIBUTOR IN ISRAEL FOR LEADING BIOPHARMACEUTICAL COMPANIES EXPANDING THE DISTRIBUTION SEGMENT MODEL TO THE MENA REGION More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market Key areas: pl
Slide 9: M&A Transactions
M&A TRANSACTIONS EXPECT TO SECURE NEW BUSINESS DEVELOPMENT AND M&A TRANSACTIONS DURING 2025; LEVERAGING OVERALL FINANCIAL STRENGTH AND COMMERCIAL INFRASTRUCTURE Screening strategic business development opportunities to identify potential acquisition or in - licensing to accelerate long - term growth
Slide 10: Kamada Plasma: Expanding Vertical Integration & Revenue Growth
KAMADA PLASMA EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH Collecting hyper - immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Operating three plasma collection centers in Texas; Houston, San Antonio and Beaumont Houston center now FDA approved
Slide 11: Inhaled AAT Phase 3 Pivotal Study
$2 Billion A substantial market opportunity (2028) 1 Based on expected changes to the statistical analysis plan, intend to reduce the study sample size to approximately 180 patients , and conduct an interim futility analysis by the end of 2025 FDA reconfirmed overall study design, endorsed positive
Slide 12: Strong H1 Financial Results
STRONG H1 - 25 FINANCIAL RESULTS 12 Adjusted EBITDA is defined as net income, plus (i) tax expense, (ii) financial income (expense),net, (iii) depreciation and amortization; and (v) non - cash share - based compensation expenses DETAILS FY 2024 Q2/24 Q2/25 H1/24 H1/25 US $ M Driven by KAMRAB® & GLAS
Slide 13: Kamada - A Global Biopharmaceutical Company
KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 15% CAGR (from 2021) $178 - 182M 2025 Revenues Guidance $40 - 44M 1 2025 Adj. EBIDTA Guidance 4 Pillars of Growth A LEADER IN SPECIALTY PLASMA THERAPIES, WITH A PORTFOLIO OF MAR
Slide 14: Thank You
THANK YOU NASDAQ: KMDA; TASE: KMDA.TA www.kamada.com
Slide 15: Non-IFRS Measures – Adjusted EBITDA
15 NON - IFRS MEASURES – ADJUSTED EBITDA Adjusted EBITDA is defined as net income, plus (i) tax expense, (ii) financial income (expense),net, (iii) depreciation and amortization; and (v) non - cash share - based compensation expenses 2024 Q2/24 Q2/25 H1/24 H1/25 US $ M 14.5 4.4 7.4 6.8 11.3 NET PROF
Slide 16: FDA-Approved Specialty Plasma Products
16 6 FDA - APPROVED SPECIALTY PLASMA PRODUCTS KEY FOCUS ON TRANSPLANTS & RARE CONDITIONS KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection CYTOGAM® [Cytomegalovirus Immune Globulin (Human)] Prophylaxis of CMV disease associated with transplants HEPGAM B® [Hepatit